SAN DIEGO — A sepsis pathogen diagnostic that provides species-specific results in three to five hours may be more sensitive than blood culture, according to data from a small study presented by the test’s manufacturer, T2 Biosystems, Inc., at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the International Society of Chemotherapy (ICC) joint meeting in San Diego, CA.
According to the data, 23 patients who had tested positive for a Candida infection using blood culture and had been administered antifungal therapy were enrolled in the study.
The study compared the results of T2Candida and blood culture during the first week of treatment. Patient specimens were collected on the day of enrollment and days three, five and seven, provided that patients remained positive by either test method. Blood culture and T2Candida test results were compared to determine which method was most accurate for monitoring those patients.
The researchers noted that T2Candida demonstrated greater accuracy in detecting invasive candidiasis, or the presence of the Candida infection, delivering 17 positive results during the testing period for nine patients with candidemia who were receiving antifungal therapy, while blood culture delivered only three positive results within the same patient setting.
In one case, T2Candida identified a case of intra-abdominal candidiasis caused by Candida albicans that was not detected by multiple blood cultures.
The researchers concluded that the test may be a useful tool for detection, species identification, and patient monitoring for cases of candidemia and invasive candidiasis to facilitate initiation or cessation of therapy, as well as for controlling the source of the infection.
The diagnostic panel was approved by the FDA in September 2014 and is moving into hospitals now.
1. Pappas P, et al. Presented at: ICAAC/ICC 2015; Sept. 17-21, 2015; San Diego.